Divergent FOXA1 mutations drive prostate tumorigenesis and therapy-resistant cellular plasticity
Science · 04.09.2025 · 389 (6764)
DOI: 10.1126/science.adv2367 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science, erschienen am 04.09.2025. Verfasst von Sanjana Eyunni und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Michigan, Ann Arbor, MI, USA. Hauptthemen laut MEDLINE: Adenocarcinoma, Carcinogenesis, Cell Plasticity, Hepatocyte Nuclear Factor 3-alpha. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS, Howard Hughes Medical Institute.
Abstract (Originalsprache)
FOXA1 is altered in 10 to 40% of prostate cancers, yet its oncogenic mechanisms remain uncharacterized in vivo. We developed knock-in mouse models representing distinct classes of FOXA1 mutations. Histopathological and multiomic analyses of prostate tissues and organoids revealed that Class 1 mutations, in conjunction with p53 inactivation, drive androgen-dependent adenocarcinomas through coactivation of mTORC1/2 and oncogenic AR signaling stemming from chimeric AR-half enhancers. By contrast, Class 2 mutations induce intraluminal plasticity by reprogramming differentiated luminal cells into a progenitor-like state through activation of KLF5 and AP-1 neo-enhancer circuitries, which enables enhanced survival and proliferation even under castrate androgen levels. Our findings establish FOXA1 as a multifaceted oncogene, with distinct mutational classes divergently evolving to drive prostate tumorigenesis or therapy-resistant progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
- Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
- Molecular and Cellular Pathology Program, University of Michigan, Ann Arbor, MI, USA.
- Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA.
- Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI, USA.
- Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.
ORCID-Profile: Sanjana Eyunni, Rahul Mannan, Eleanor Young, Qiuyang Zhang, Somnath Mahapatra, Jean Ching-Yi Tien, James M George, Mustapha Jaber, Hamzah Hakkani, Sandra E Carson, Abigail J Todd, Noshad Hosseini, Ryan J Rebernick, Xuhong Cao, Rui Wang, Rohit Mehra, Arul M Chinnaiyan, Abhijit Parolia
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- Howard Hughes Medical Institute
Zitieren
APA
Eyunni, S., Mannan, R., Zhang, Y., Young, E., Zhang, Q., Luo, J., Pang, M., Mahapatra, S., Tien, J. C., George, J. M., Jaber, M., Hakkani, H., Carson, S. E., Todd, A. J., Hosseini, N., Gondal, M., Rebernick, R. J., Cao, X., Su, F., …, & Parolia, A. (2025). Divergent FOXA1 mutations drive prostate tumorigenesis and therapy-resistant cellular plasticity. Science, 389(6764). https://doi.org/10.1126/science.adv2367
Vancouver
Eyunni S, Mannan R, Zhang Y, Young E, Zhang Q, Luo J, et al. Divergent FOXA1 mutations drive prostate tumorigenesis and therapy-resistant cellular plasticity. Science. 2025;389(6764). doi:10.1126/science.adv2367
BibTeX
@article{Eyunni2025,
author = {Eyunni, Sanjana and Mannan, Rahul and Zhang, Yuping and Young, Eleanor and Zhang, Qiuyang and Luo, Jie and Pang, Matthew and Mahapatra, Somnath and Tien, Jean Ching-Yi and George, James M and Jaber, Mustapha and Hakkani, Hamzah and Carson, Sandra E and Todd, Abigail J and Hosseini, Noshad and Gondal, Mahnoor and Rebernick, Ryan J and Cao, Xuhong and Su, Fengyun and Wang, Rui and Mehra, Rohit and Li, Jing and Cieslik, Marcin and Chinnaiyan, Arul M and Parolia, Abhijit},
title = {Divergent FOXA1 mutations drive prostate tumorigenesis and therapy-resistant cellular plasticity},
journal = {Science},
year = {2025},
volume = {389},
number = {6764},
doi = {10.1126/science.adv2367}
}
EUVIMED